|
Dec 22
|
Mendus announces clinical pipeline update
|
|
Dec 6
|
Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML
|
|
Dec 5
|
Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6
|
|
Dec 4
|
Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023
|
|
Nov 9
|
Mendus AB Interim Report January – September 2023
|
|
Nov 6
|
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
|
|
Nov 3
|
Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal
|
|
Nov 2
|
Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data
|
|
Sep 28
|
Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC
|
|
Aug 29
|
Mendus AB (publ) Interim Report January – June 2023
|